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ABSTRACT The objectives of this study were to perform genomic and phenotypic
characterization of antimicrobial resistance in Neisseria gonorrhoeae isolates recov-
ered from urine samples from patients in St. Louis, MO, USA. Sixty-four clinical iso-
lates were banked over a 2-year period and subjected to antimicrobial susceptibility
testing (AST) by Kirby-Bauer disk diffusion (penicillin, tetracycline, cefuroxime, and
ciprofloxacin) and gradient diffusion (tetracycline, doxycycline, azithromycin, ceftriax-
one, cefixime, ciprofloxacin, gemifloxacin, and delafloxacin). The medical records for
the patients were evaluated to determine the demographics, location, and pre-
scribed treatment regimen. Isolate draft genomes were assembled from Illumina
shotgun sequencing data, and resistance determinants were identified by ResFinder
and PointFinder. Of the 64 isolates, 97% were nonsusceptible to penicillin, with re-
sistant isolates all containing the blaTEM-1b gene; 78 and 81% of isolates were non-
susceptible to tetracycline and doxycycline, respectively, with resistant isolates all
containing the tet(M) gene. One isolate was classified as non-wild-type to azithromy-
cin, and all isolates were susceptible to ceftriaxone; 89% of patients received this com-
bination of drugs as first-line therapy. Six percent of isolates were resistant to ciprofloxa-
cin, with most resistant isolates containing multiple gyrA and parC mutations. Correlation
between disk and gradient diffusion AST devices was high for tetracycline and cipro-
floxacin (R2  99% for both). The rates of N. gonorrhoeae antibiotic resistance in St.
Louis are comparable to current rates reported nationally, except ciprofloxacin resistance
was less common in our cohort. Strong associations between specific genetic markers
and phenotypic susceptibility testing hold promise for the utility of genotype-based di-
agnostic assays to guide directed antibiotic therapy.
IMPORTANCE Neisseria gonorrhoeae causes the sexually transmitted infection gonor-
rhea, which is most commonly diagnosed using a DNA-based detection method that
does not require growth and isolation of N. gonorrhoeae in the laboratory. This is
problematic because the rates of antibiotic resistance in N. gonorrhoeae are increas-
ing, but without isolating the organism in the clinical laboratory, antibiotic suscepti-
bility testing cannot be performed on strains recovered from clinical specimens. We
observed an increase in the frequency of urine cultures growing N. gonorrhoeae af-
ter we implemented a total laboratory automation system for culture in our clinical
laboratory. Here, we report on the rates of resistance to multiple historically used,
first-line, and potential future-use antibiotics for 64 N. gonorrhoeae isolates. We
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found that the rates of antibiotic resistance in our isolates were comparable to na-
tional rates. Additionally, resistance to specific antibiotics correlated closely with the
presence of genetic resistance genes, suggesting that DNA-based tests could also be
designed to guide antibiotic therapy for treating gonorrhea.
KEYWORDS Neisseria gonorrhoeae, gonorrhea, urine culture
Neisseria gonorrhoeae, the microorganism that causes the sexually transmitteddisease gonorrhea, infects approximately one million people in the United States
annually (1, 2). Historically, penicillin and doxycycline have been used to treat gonor-
rhea; however, the emergence of N. gonorrhoeae strains resistant to these antibiotics in
the 1980s prompted the implementation of alternative treatment strategies. While the
antimicrobial regimen of choice recommended in clinical guidelines has varied over the
past decades, today, single-dose ceftriaxone plus azithromycin combination therapy is
the standard of care for the treatment of gonorrhea in the United States and much of
the world (3–7). With the advent of direct-from-specimen nucleic acid amplification
testing (NAAT), gonorrhea can now be diagnosed and treated in a single clinic or
emergency room encounter. NAAT is rapid, highly sensitive, and specific; as such, it has
become the standard of care for diagnosing gonorrhea and has largely replaced
culture-based diagnosis of N. gonorrhoeae, which is slow and suffers from poor sensi-
tivity (8, 9). Importantly however, culture is a prerequisite for performing antimicrobial
susceptibility testing (AST) on an organism, and recent trends suggest that N. gonor-
rhoeae is becoming increasingly resistant to antibiotics, including azithromycin and
ceftriaxone (7, 10–14) (for a review, see reference 15).
Within the past 3 years, the clinical microbiology laboratory at Barnes-Jewish Hospital
(affiliated with Washington University in St. Louis)—a central laboratory for 5 hospitals in a
13-hospital health care system—implemented a total laboratory automation system for
culture-based microbiology (BD KiestraTLA; Becton-Dickinson). After these changes, the
laboratory observed a dramatic increase in the number of routine urine cultures from which
fastidious microorganisms were recovered (16). This included a large increase in routine
urine cultures growing N. gonorrhoeae, which typically does not grow on blood agar
medium under atmospheric oxygen tension commonly used for conventional urine culture
(Fig. 1A). Here, we use whole-genome sequencing and AST to characterize the epidemiol-
ogy and antimicrobial resistance patterns and establish genotype-phenotype correlations
for 64 N. gonorrhoeae isolates from patients in the St. Louis area.
RESULTS
Sample set and patient demographics. Of 74 isolates initially identified as N.
gonorrhoeae during routine workup by matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF MS) (BioTyper) in the clinical microbi-
ology laboratory at Barnes-Jewish Hospital between November 2015 and October 2017,
64 met all inclusion criteria for this study, including recovery from cryopreservation,
confirmed identification as N. gonorrhoeae by MALDI-TOF MS (Vitek MS) after subcul-
ture, and complete patient records. Of note, there was 96% agreement between the
two MALDI-TOF MS methods.
The majority of the isolates in our sample set came from young black men living in
North St. Louis, MO. All were symptomatic with some degree of urogenital discomfort
(e.g., “urethral discharge” or “dysuria”); urine cultures were performed as part of a
general urogenital tract infection workup at the discretion of the treating physician. The
mean age of patients was 27 years old (standard deviation [SD], 9.6 years), but ages
ranged from 15 to 58 years of age (Table 1). Of 64 (93.8%) patients, 60 were male, and
59/64 (92.2%) of patients were black. Two black women, two white women, and three
white men were also represented in our data set. Of 64 isolates, 54 (84.4%) isolates
came from patients residing in zip codes from the predominantly African American
community of North St. Louis (Fig. 1B). Isolates from other locations were rare and
originated from patients scattered throughout more demographically heterogeneous
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neighborhoods in South St. Louis (3/64 [4.7%]) or St. Louis suburbs in Illinois (5/64
[7.8%]).
Over the time frame when this study was conducted, N. gonorrhoeae was isolated
from 0.064% of all urine cultures performed, representing 0.3% of all uropathogens
recovered (16). NAAT was the predominant method of gonorrhea diagnosis, with 60/64
(93.8%) isolates having a corresponding NAAT test at the time of specimen collection;
all were positive except for one that was “indeterminate.” The converse was difficult to
assess, given the high prevalence of gonorrhea within our laboratory’s catchment area
and the superior sensitivity of NAAT over culture as a primary method for diagnosis.
Therefore, we were unable to estimate the percentage of specimens that were positive
by NAAT but negative by urine culture. Most patients (37/64 [57.8%]) had no concur-
rent sexually transmitted infections (STIs). However, concurrent infections (as docu-
mented via review of the electronic medical record) with Chlamydia trachomatis (18/64
[28.1%]), Trichomonas vaginalis (2/64 [3.1%]), HIV (2/64 [3.1%]), and hepatitis C virus
(HCV) (1/64 [1.6%]) were identified in a subset of patients. At the time of presentation,
FIG 1 Recovery of N. gonorrhoeae from urine cultures in the St. Louis area. (A) Blood agar plate showing
growth of N. gonorrhoeae from routine urine culture performed on a total laboratory automation system
(the BD KiestraTLA). Colonies appear nonhemolytic, pin-point, and clear/gray/white in color. (B) Map of
the St. Louis metropolitan area showing the primary residence of the patient from which each isolate was
obtained at the zip code level or with an arrow indicating the direction of zip codes that are not on the
map. Heat mapping highlights the number of patients per zip code, with darker red indicating more
patients per zip code. BJH, Barnes-Jewish Hospital; SLCH, St. Louis Children’s Hospital.
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57/64 (89%) individuals received standard-of-care antimicrobial therapy for gonorrhea:
single-dose azithromycin (1 g) plus ceftriaxone (250 mg) (Table 1).
Antimicrobial susceptibility testing of N. gonorrhoeae isolates. Given recent
reports of increasing antibiotic resistance among N. gonorrhoeae isolates, we evaluated
resistance to several antibiotics in our sample set. We assessed antibiotics from the
tetracycline, quinolone, beta-lactam, and macrolide classes that were either used
historically to treat gonorrhea or are used currently as first-line agents for treating
gonorrhea or have been proposed as future therapies for treating multidrug-resistant
N. gonorrhoeae (17).
We first assessed the distribution of MICs (or zone diameters) displayed by N.
gonorrhoeae isolates against each antibiotic. For penicillin, tetracycline, and doxycy-
TABLE 1 Demographics, diagnosis, and antimicrobial therapy for study subjects (n  64)
Characteristica













Azithromycin (1 g)  ceftriaxone (250 mg) 34
Azithromycin (1 g)  ceftriaxone (250 mg)  metronidazole (2 g) 23 (35.9)
Azithromycin (1 g)  ceftriaxone (250 mg)  ciprofloxacin
(500 mg BID for 7 days)
1 (1.6)
Ciprofloxacin (500 mg BID for 14 days) 1 (1.6)
Cephalexin 500 mg BID for 7 daysb 1 (1.6)
Azithromycin (1 g)  TMP-SMX 1 (1.6)
Metronidazole (2 g) onlyc 1 (1.6)
Treatment information not available 2 (1.6)
Neisseria gonorrhoeae NAAT test result
Positive for N. gonorrhoeae (of tested subjects) 59 (98.3)
Negative for N. gonorrhoeae (of tested subjects) 0 (0.0)
Indeterminate (of tested subjects) 1 (1.7)
NAAT not performed (of total subjects) 4 (6.3)
Concurrent STI
None documented 37 (57.8)
Chlamydia trachomatis 18 (28.1)
Trichomonas vaginalis 2 (3.1)
HIV 2 (3.1)
HCV 1 (1.6)
Not screened or data not available 4 (6.3)
Specimen source
Urine sample 58 (90.6)
Genital swab 4 (6.3)
Wound swab 1 (1.6)
Ocular swab 1 (1.6)
Culture method
Kiestra TLA 52 (81.3)
Conventional microbiology workflow 12 (18.8)
aAbbreviations: BID, twice a day; TMP-SMX, trimethoprim-sulfamethoxazole.
bComplicated by pyelonephritis.
cThis patient, treated with metronidazole only, presented 2 weeks later and was treated with azithromycin
(1 g) plus ceftriaxone (250 mg).
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cline, isolates formed a multimodal distribution of MICs (or zone diameters) that
roughly corresponded to the susceptible (S), intermediate (I), and resistant (R) catego-
ries of antimicrobial susceptibility (Fig. 2A and B). A bimodal distribution of MICs was
also observed for azithromycin, with a group of isolates straddling the lower bound of
the clinical breakpoint. In contrast, the susceptibility of isolates to cephalosporins was
distributed about a mean that resided deep within the susceptible category. This was
also true for the quinolone class of antibiotics, with the exception of four outliers that
displayed increased MICs to ciprofloxacin, gemifloxacin, and delafloxacin.
The greatest percentage of isolates with nonsusceptible phenotypes (i.e., resistant or
intermediate) were found for penicillin (96.9%: 7.8% R, 89.0% I), doxycycline (81.0%),
and tetracycline (40.6% by disk diffusion; 78.1% by gradient diffusion) (Fig. 2C). Isolates
were highly susceptible to first-line therapy: only 1 isolate of 64 isolates (1.6%) was
non-wild-type to azithromycin, and none of the 64 isolates (0%) were resistant to
ceftriaxone (or any of the other cephalosporins tested). Among quinolone antibiotics,
the highest rate of nonsusceptibility was seen for ciprofloxacin (5/64 [7.8%]), with four
of the ciprofloxacin-resistant isolates also testing nonsusceptible to gemifloxacin (4/64
[6.25%]) and displaying increased MICs for delafloxacin. These four isolates also tested
nonsusceptible to penicillin, doxycycline, and tetracycline, indicative of a multidrug-
resistant phenotype (Fig. 2D).
We also examined categorical agreement between the disk and gradient diffusion
methods for tetracycline and ciprofloxacin. Isolates displayed a wide range of suscep-
tibilities to tetracycline, with zone diameter correlating strongly with MIC (R2  99%
using a least-squares nonlinear fit model; Fig. 3). However, this corresponded to only
40/64 isolates (62.5%) having categorical agreement, with the remaining 24/64 isolates
(37.5%) testing susceptible by disk diffusion but intermediate by gradient diffusion.
Nonetheless, there were zero major or very major errors for tetracycline disk versus
gradient diffusion methods. Isolates with resistance to ciprofloxacin were uncommon;
nonetheless, the correlation between zone diameter and MIC was very high (R2  99%),
as was categorical agreement (100%).
Genetic determinants of antimicrobial resistance in N. gonorrhoeae isolates.
For most of the antibiotics we tested, the zone sizes (or MICs) were not normally
distributed (as measured by the D’Agostino-Pearson omnibus normality test; Fig. 2A
and B)—a potential indication of acquired resistance genes and/or mutations in a
subset of isolates. To explore this observation further, we performed whole-genome
sequencing on each isolate. The ResFinder and PointFinder databases were used to
identify known genes and mutations (collectively referred to as “resistance determi-
nants”), respectively. We detected several penicillin resistance determinants; however,
only acquisition of the blaTEM-1b beta-lactamase gene was consistently associated with
penicillin resistance and was found in 100% of penicillin-resistant isolates (Fig. 4A). As
expected, the presence of blaTEM-1b was not associated with increased cephalosporin
MICs (or reduced zone sizes), nor were any of the other resistance determinants we
examined (Fig. 4B).
Within the tetracycline class, acquisition of tet(M) was highly associated with resis-
tance to both tetracycline and doxycycline, with all five (100%) resistant isolates
containing tet(M) (Fig. 4C). All five isolates resistant to tetracycline also had the rpsJ
V57M mutation, but isolates containing the rpsJ mutation yet lacking tet(M) were not
resistant.
Only one of five isolates with increased MICs to azithromycin contained an estab-
lished multidrug resistance determinant (an mtrR promoter mutation), although this
particular isolate still met the definition of “wild type.”
The genotype-phenotype correlation for the quinolone antibiotics was less straight-
forward. All four isolates with known resistance mutations in gyrA and parC were
resistant to ciprofloxacin, with the exception of one isolate with a gyrA S91F mutation
which was categorized as “intermediate” to ciprofloxacin (MIC  0.125 g/ml). This
particular isolate contained only the gyrA S91F mutation whereas the other three
isolates contained a gyrA D95G mutation in addition to the gyrA S91F mutation
Antibiotic Resistance of N. gonorrhoeae from Urine
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FIG 2 Antimicrobial susceptibility of N. gonorrhoeae isolates. (A and B) Clinical isolates (n  64) were subjected to AST via the disk
diffusion method (A) or gradient diffusion (i.e., “Etest”) method (B). Zone-of-inhibition diameters (A) and MICs (B) are shown. Each black
circle represents the value for one isolate, and the geometric mean (horizontal black bar) with 95% confidence interval (error bars)
for the different treatment groups are shown. For isolates with MICs that were off the measurable scale, a value of 65 mm (disk) or
the lowest value (gradient strip) was assigned. Throughout the figure, the breakpoints for each antibiotic are shown by colors: green,
susceptible; yellow, intermediate; red, resistant (except for azithromycin, where green represents “wild-type” and red represents
“non-wild type.” CLSI breakpoints were used with the following exceptions: doxycycline breakpoints were inferred from tetracycline;
gemifloxacin breakpoints were inferred from ciprofloxacin; delafloxacin breakpoints were inferred from ciprofloxacin; and EUCAST
(Continued on next page)
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(Fig. 4D). Accordingly, the isolate with the lone gyrA S91F mutation was also susceptible
to gemifloxacin and delafloxacin, whereas the other isolates containing multiple quin-
olone resistance determinants tested “intermediate” to gemifloxacin and had increased
MICs to delafloxacin. Finally, one isolate contained no known quinolone resistance
determinants but repeatedly tested as resistant to ciprofloxacin with increased MICs to
gemifloxacin and delafloxacin.
Phylogenetic analysis of N. gonorrhoeae isolates. To examine relationships be-
tween isolates, we constructed a core genome phylogeny using PRANK and raxML on
the 1,563 genes shared by the genomes collected in our investigation and the WHO
reference strains (18, 19) (Fig. 5). Midpoint rooting of the phylogenetic tree showed that
the collected isolates fell within three major clades. WHOF/WHOW strains were in the
first cluster, WHOO strain was in the second cluster, and the remaining WHO strains
were in the third cluster. To identify putative transmission clusters, we labeled each
isolate with its corresponding zip code; however, transmission clusters were not
identified. However, we observed associations between resistance determinants and
position of the isolates on the phylogenetic tree. blaTEM-1b was located only in isolates
within the first cluster, and tet(M) was found only in the second cluster.
DISCUSSION
Because NAAT is the standard of care for diagnosis of N. gonorrhoeae, clinical isolates
for detailed phenotypic and genotypic characterization are scarce. New culture meth-
ods facilitated enhanced recovery of N. gonorrhoeae isolates in our laboratory, and
subsequently, we characterized 64 patient isolates, including analysis of demography,
geography, AST, and whole-genome sequencing.
As expected, the rates of antibiotic resistance to historically used antibiotics such as
penicillin and doxycycline were high and were correlated with the presence of the
blaTEM-1b and tet(M) genes, respectively. However, almost no resistance to current
first-line antibiotics, including azithromycin or drugs in the cephalosporin class was
detected, consistent with low rates of resistance to first-line antibiotics reported
FIG 2 Legend (Continued)
breakpoints were used for ceftriaxone. (C) The percentages of isolates that are susceptible (S), intermediate (I), and resistant (R) are
shown with the method of susceptibility testing for each drug denoted by a “D” (for disk diffusion) or an “E” (for Etest/gradient
diffusion methods) in parentheses after the drug (note that susceptibility results for doxycycline were available for only 63 isolates).
(D) Each row in panel D shows the susceptibility profile of a single isolate, with isolates hierarchically clustered by Euclidean distance
after assigning a score to each isolate (scores were assigned as follows: 3 for resistant, 2 for intermediate, and 1 for susceptible) to
create a matrix. The dendrogram on the left side represents clustering of the individual isolates (n  64), and the dendrogram above
the clustermap represents clustering of the antibiotics (n  12). The clustermap was generated in python3 with seaborn (https://
seaborn.pydata.org/). The method of susceptibility testing for each drug is denoted by a “D” (for disk diffusion) or an “E” (for
Etest/gradient diffusion methods). (Note that susceptibility results for doxycycline were available for only 63 isolates.).
FIG 3 Gradient diffusion versus disk diffusion methods for antimicrobial resistance testing of N.
gonorrhoeae isolates. The susceptibility of each isolate to tetracycline and ciprofloxacin was assessed by
gradient diffusion and disk diffusion for each antibiotic. MIC, as determined by gradient diffusion, is
shown on the y axis (natural log scale) with dashed lines denoting the breakpoints between susceptible
(S), intermediate (I), and resistant (R). Disk diameter is shown on the x axis. Colors demarcate zones of
categorical concordance between the two test methods (green for S, yellow for I, red for R).
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throughout the United States (1). We also found a relatively low rate of ciprofloxacin
resistance (6%) in the N. gonorrhoeae isolates in our study, which is in contrast to the
rapid increase in resistance to quinolone antibiotics seen nationwide (approximately 20
to 40% of isolates in 2016, depending on location) (1, 20). However, several of the
ciprofloxacin-resistant isolates we identified contained a combination of mutations in
the gyrA and parC genes known to confer high-level resistance to ciprofloxacin (15, 21).
These isolates also displayed increased MICs to quinolones that have been proposed as
next-generation agents to combat multidrug-resistant N. gonorrhoeae— gemifloxacin
and delafloxacin—suggesting that determinants of resistance to ciprofloxacin may be
poised to rapidly acquire resistance and/or exhibit cross-resistance to other antibiotics
in the quinolone class (17, 21). Furthermore, all isolates containing quinolone resistance
determinants were also resistant to antibiotics from at least two other classes, suggest-
ing that quinolone resistance may be a marker of multidrug resistance and that this
association could be a useful tool as a surrogate for multidrug resistance to incorporate
into future molecular diagnostic methods. One limitation of the antimicrobial resistance
characterization in our study is that opportunistically available isolates from routine
urine cultures could have biased our recovery of antibiotic-resistant organisms.
Given the AST profiles of the N. gonorrhoeae isolates in our study and considering
that the majority of patients (57/64 [89%]) received single-dose azithromycin (1 g) plus
ceftriaxone (250 mg) at the time of presentation (Table 1), we predict that the cure rate
for gonorrhea using empirical treatment in our patient population is high. The high
FIG 4 Correlation of resistance phenotypes with known resistance determinants in N. gonorrhoeae isolates.
Whole-genome sequencing was performed on all clinical isolates (n  64), and common antimicrobial
resistance determinants were identified. Each graph shows the zone of inhibition or MIC for a drug with the
corresponding resistance determinants displayed on the x axis. Only determinants that were present in one
or more isolates are shown; if an isolate harbored more than one resistance determinant, it is displayed for
each determinant. Colors denote breakpoints for each antibiotic: green, susceptible; yellow, intermediate; red,
resistant. P values show the results of Mann-Whitney U tests between selected groups. (A) Penicillin; (B)
ceftriaxone (results for cefuroxime and cefixime were similar); (C) doxycycline (results for tetracycline were
virtually identical); (D) ciprofloxacin (results for delafloxacin and gemifloxacin were similar).
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FIG 5 Core genome phylogenetic analysis with geographic information and antibiotic resistance determinants. A maximum likelihood
phylogenetic tree was constructed based upon the 1,563 core gene alignment created in PRANK. Bootstrap support values below 90% are shown
(Continued on next page)
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percentage of N. gonorrhoeae-positive cultures that were concurrently diagnosed by
NAAT (Table 1) also implies that few additional cases are diagnosed by urine culture.
Taken together, these findings suggest that the current standard of care for N. gonor-
rhoeae diagnosis, NAAT, continues to be appropriate in our patient population, except
in cases of suspected treatment failure when cultured isolates are necessary for AST.
Nevertheless, global trends in N. gonorrhoeae antimicrobial resistance portend the
need for AST methods that are more accessible than the agar dilution method, which
is labor-intensive and performed only in reference laboratories. Studies comparing agar
dilution to gradient diffusion devices for several antibiotics have demonstrated accept-
able performance characteristics of gradient diffusion devices compared to agar dilu-
tion for several antibiotics (22–24). We found a high degree of correlation between
gradient diffusion and disk diffusion AST results for tetracycline and ciprofloxacin, as
reflected by the observed R2 values, suggesting that disk diffusion may also be an
acceptable and accessible method of tetracycline and ciprofloxacin resistance testing in
N. gonorrhoeae; however, this may require future reassessment of the tetracycline
breakpoints. Although no major or very major errors occurred, 24/64 isolates (37.5%)
tested susceptible by disk diffusion but intermediate by gradient diffusion.
Given the ongoing challenges of performing AST on N. gonorrhoeae isolates in the
clinical setting, direct-from-specimen genotyping, especially when multiplexed with
NAAT, could have a major impact on guiding the choice of antimicrobial therapy (25).
Indeed, a recent proof-of-concept study showed that ciprofloxacin therapy was 100%
effective in curing gonorrhea caused by strains lacking resistance-conferring gyrA
mutations (26). Our study adds to a growing body of literature demonstrating strong
associations between specific genotypic markers and resistance to several antibiotics
[i.e., blaTEM-1b for penicillin, tet(M) for tetracyclines, and gyrA with or without parC for
quinolones], suggesting that additional genetic targets—via a targeted or whole-
genome sequencing approach—may enable the effective use of antimicrobials that are
no longer appropriate for use as empirical therapy (27–29). However, our identification
of one ciprofloxacin-resistant isolate lacking any known quinolone resistance determi-
nants highlights the current limitations of this approach and the need for ongoing
efforts to interrogate the resistome of N. gonorrhoeae strains and expand the repository
of genetic determinants of phenotypic resistance.
MATERIALS AND METHODS
Ethics statement. Prior to study initiation, this investigation was reviewed by the institutional review
board at the Washington University School of Medicine and approved with a waiver of consent.
Clinical isolates. Growth of bacterial isolates from clinical specimens identified as N. gonorrhoeae by
matrix-assisted laser desorption ionizationtime of flight mass spectrometry (MALDI-TOF MS) using the
BioTyper (Bruker Corporation) were frozen at 80°C in reconstituted powdered milk. Prior to antimicro-
bial susceptibility testing (AST) and sequencing, isolates were thawed and subcultured twice on
chocolate agar (Hardy Diagnostics) incubated at 35°C  2°C with 5% CO2, and the organism identification
was confirmed with Vitek MS MALDI-TOF MS (bioMérieux). Patient characteristics such as age, sex,
coinfections, and zip code of residence, were obtained from retrospective review of the electronic
medical record.
Antimicrobial susceptibility testing. After two subcultures, plates containing GC II agar with
IsoVitaleX enrichment (Becton-Dickinson) were inoculated with a 0.5 McFarland direct-colony suspension
of each isolate. The plates were incubated at 35°C  2°C with 5% CO2 and read by two independent
readers after 24 h of incubation. Quality control was performed each day of testing (N. gonorrhoeae ATCC
49226 and Escherichia coli ATCC 25922).
For AST results, results from two independent readers were averaged and then rounded up to the
nearest doubling dilution (gradient diffusion method only). For isolates with AST values that were off
the measurable scale, a value of 65 mm (disk) or the lowest value on the gradient strip was assigned as
the value for the purpose of analysis. Categorical results were determined by comparing these results to
established clinical breakpoint criteria from the Clinical and Laboratory Standards Institute (CLSI)
M100-S29 document (30) with the following exceptions. Doxycycline breakpoints were inferred from
FIG 5 Legend (Continued)
at the corresponding branch-points. The geographic origin of each isolate (zip code) is denoted by color adjacent to the isolate name. The
presence or absence of an antibiotic resistance determinant in a particular isolate is denoted by a colored or blank square, respectively. If
resistance determinants in the ResFinder or PointFinder databases were not found in any of the isolates, they are not shown in the figure.
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tetracycline (30). Gemifloxacin and delafloxacin breakpoints were inferred from ciprofloxacin (30). The
recently published CLSI M100-S29 breakpoint was used for azithromycin (30). The European Union
Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (31) were used for ceftriaxone.
Additional information on AST devices, including manufacturer and breakpoint criteria, can be found in
Table S1 in the supplemental material.
Whole-genome sequencing and analysis. Sample preparation, sequencing, and sequence analysis
were performed as described previously (32) using 12 World Health Organization (WHO) reference
genomes (18) (Table S2). Genomic DNA was obtained from pure N. gonorrhoeae cultures using the
QIAmp BiOstic Bacteremia DNA kit (Qiagen, Germantown, MD, USA), and 0.5 ng of genomic DNA was
used to create sequencing libraries with the Nextera kit (Illumina, San Diego, CA, USA) (33). Samples were
pooled and sequenced on an Illumina NextSeq to obtain 2  150 bp reads. The raw reads and Illumina
adapters were removed with trimmomatic v.38, and contaminating DNA was removed with DeconSeq
v.4.3 (34, 35). Processed reads were used to de novo assemble scaffolds with SPAdes v3.13.0 (36). Quality
statistics were obtained with QUAST v4.5, and protein-coding sequences were identified with prokka
v1.12 (Table S3) (37, 38). Of 64 genomes, 61 passed in silico quality assessment and were used in genomic
analysis. We additionally gathered World Health Organization (WHO) reference N. gonorrhoeae genomes
and identified all protein-coding sequences with prokka (18). Coding sequences were clustered at 95%
identity with roary v3.12.0, and the 1,563 core genes were used to create a core genome alignment with
PRANK v1.0 (19, 39). The core genome alignment was converted to a maximum likelihood phylogenetic
tree with RAxML and viewed in iToL with an overlay showing zip code and identified resistance
determinant (40, 41). Vertically transmitted mutations associated with antimicrobial resistance were
identified with the N. gonorrhoeae database using PointFinder v4.0 on the scaffolds.fasta file from
SPAdes. Acquired antibiotic resistance genes were identified with ResFinder v4.0 (42).
Data analysis. Data were tabulated in Excel (Microsoft), where demographic and summary statistics
were calculated. Data were then imported into Prism version 7 (GraphPad) for graphing and group
comparisons. All statistical methods are described in the corresponding figure legends. Color overlays
and final figures were prepared in Illustrator CC 2017 (Adobe).
Data availability. All genomes used in this study have been deposited into the NCBI Whole Genome
Shotgun Database associated with BioProject accession no. PRJNA504667.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSphere.00373-19.
TABLE S1, XLSX file, 0.01 MB.
TABLE S2, XLSX file, 0.1 MB.
TABLE S3, XLSX file, 0.03 MB.
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